
Opinion|Videos|January 2, 2025
Newly Diagnosed mHSPC: First-Line Treatment Options
Author(s)Evan Y. Yu, MD
Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or androgen receptor pathway inhibitors (ARPIs) such as abiraterone or enzalutamide, with the choice of frontline treatment depending on factors such as disease burden and patient characteristics, while also considering the structural and physical differences between these ARPIs, which may influence their efficacy and adverse effect profiles.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What systemic therapy options would you discuss with this patient?
- Which do you consider for frontline treatment?
- Thinking about the individual ARPI used in this setting, what are their similarities and differences in terms of structural formula and physical properties?
Advertisement
Related to this article

During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.

The designation supports development of elticertinib for patients with EGFR exon 20 insertion–mutated NSCLC progressing after platinum-based chemotherapy and amivantamab.

Updated THIO-101 data showed an 88% DCR with ateganosine followed by cemiplimab in third-line NSCLC after immunotherapy and chemotherapy.

Galinpepimut-S maintenance improved median OS to 24.0 vs 14.7 months with best available treatment in AML in second remission, a 41% reduction in risk of death.

The FDA accepted a supplemental application for selinexor plus ruxolitinib in myelofibrosis, setting a June 28, 2027, target action date based on phase 3 SENTRY findings.

The FDA has approved neladalkib for TKI-pretreated advanced ALK-positive NSCLC based on ALKOVE-1, requiring only 1 prior line of treatment in those who received prior alectinib.

The designation supports development of onvansertib plus FOLFIRI/bevacizumab as first-line therapy for KRAS- or NRAS-mutated metastatic colorectal cancer, based on phase 2 CRDF-004 findings.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
2
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
3
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
4
Dr Frigault on Anito-Cel’s Potential to Reduce Post CAR T Burden
5

